Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
471
resultados
Última actualización
29/10/2026 [07:34:00]
Resumen de: CN122979483A
本发明公开了一种viral enhancin protein基因及其引物探针组合和在肠炎沙门菌检测中的应用。viral enhancin protein基因的核苷酸序列如SEQ ID NO.2所示。本发明无需经过复杂的分菌、生化鉴定及血清学鉴定即可区分出肠炎沙门菌，极大缩短病原检测时间。与传统方法相比，实验条件要求低，可对病原进行定量检测，具有开发为快速检测试剂盒的良好潜力。
Resumen de: CN122954935A
本发明公开了一种通用型细菌外膜囊泡递送系统GMMA，涉及合成生物学疫苗递送技术领域，本发明先以脱氧胆酸钠法从革兰氏阴性菌提取直径 50‑100 nm 的外膜囊泡OMV，再经 1‑乙基‑3‑(3‑二甲基氨基丙基)‑碳二亚胺将三聚乙二醇胺生物素偶联至囊泡表面；将经 A67D、G71K、A82N、G84Q、S101R、A105K 六位点突变并截短为 114 aa 的单体亲和素与目标抗原通过五肽 GGGGS 融合表达，所得亲和素‑抗原融合蛋白与生物素化囊泡自组装形成 GMMA，结合亲和力 KD=6.6×10‑8；该系统无需菌株多基因改造即可加载一种或多种抗原，装载过程为可逆插拔式，囊泡结构完整，制备简便，安全性良好，适用于疫苗及其他抗原递送领域。
Resumen de: CN122937203A
本发明涉及一种基于鞭毛‑芽胞复合材料的口服疫苗制备方法和应用，有效解决传统注射型疫苗依从性差、黏膜免疫反应低的问题。首先，通过对细菌进行酸化处理、超速离心、硫酸铵盐析等步骤，提取具有天然免疫佐剂活性的鞭毛。以阳离子壳寡糖为连接臂，借助静电相互作用将鞭毛、抗原蛋白、抗原呈递细胞靶头（昆布多糖）组装为复合物，并修饰在益生菌芽孢表面，即得基于鞭毛‑芽胞复合材料的口服疫苗。本发明制备条件温和，生产成本低，制备的基于鞭毛‑芽胞复合材料的口服疫苗可有效激发肠道黏膜免疫应答，预防黏膜病原体的感染，有实际的推广应用价值。
Resumen de: US20260315404A1
0000 A prophylactic vaccine composition that is intended for mammals and birds comprises a killed whole bacterium, the bacterium being covered with a cationic agent, in particular, cationic nanoparticles.
Resumen de: US20260318913A1
0000 A portable detection system for detecting a pathogen or virus, the portable detection system comprising: at least one light source for generating an input optical signal; at least one optical sensor comprising at least one optical fibre having at least one tapered sensing region with at least one coating that reacts with a pathogen being detected, wherein the optical sensor is arranged to receive the input optical signal, communicate the input optical signal through the tapered sensing region and communicate an output optical signal from the tapered sensing region; at least one photodetector for detecting power intensity of the output optical signal, wherein the photodetector is arranged to generate an output signal based on a change in power intensity of the output power at a resonant wavelength that corresponds with the pathogen; and at least one microcontroller for controlling the light source, optical sensor and photodetector; wherein the portable detection system is arranged to cause an output to be generated based on the output signal, wherein the output is associated with the pathogen being detected.
Resumen de: US20260317405A1
The invention relates to methods of treating or preventing a disease or condition caused by or associated with a gram-negative bacterial infection in a subject in need thereof and compositions for use in such methods. More particularly, the present invention relates to agents and compositions, including concanavalin A, lactoferrin, colostrum and Ig from colostrum for use in the treatment or prevention of a disease or condition caused by or associated with a gram-negative bacterial infection and methods of using such agents and compositions.
Resumen de: CN117398456A
The invention discloses a tumor neoantigen vaccine system specifically labeled with heterologous protein and application of the tumor neoantigen vaccine system, the vaccine system is composed of a heterologous protein mRNA vaccine and a recombinant oncolytic virus, and the heterologous protein mRNA vaccine is used for inducing an organism to generate heterologous protein specific memory T cells; the recombinant oncolytic virus is used for promoting the tumor to express the microorganism-derived tumor neoantigen, when the pre-immunized memory T cells detect the marked specific neoantigen, the tumor expressing the neoantigen is quickly activated and killed, the release of the autoantigen of the tumor is promoted, and the dendritic cells phagocytize the antigen to further start the anti-tumor response, so that the anti-tumor effect is achieved. The systemic anti-tumor immune effect is activated through epitope expansion; the treatment strategy is applied to preparation of tumor immunotherapy drugs, and can quickly recognize and kill tumor cells and activate the anti-tumor immune effect.
Resumen de: CN109415772A
Provided herein are methods and compositions for detecting Salmonella Typhimurium in a sample.
Resumen de: WO2026208522A1
A microbial antibodyomics technology-based system and method for directed isolation of intestinal bacteria. Said system comprises a negative pressure driving mechanism, a filtration and impurity removal device (100) used for performing filtration and impurity removal treatment on a feces sample, a harmful bacterium adsorption assembly (210) used for removing harmful bacteria in a microbial mixture liquid, a beneficial bacterium enrichment assembly (220) used for performing positive enrichment treatment on beneficial bacteria in the microbial mixture liquid, a beneficial bacterium dissociation assembly (234) used for performing dissociation on beneficial bacterium-coupled bodies, and a beneficial bacterium collection bottle (240) used for collecting beneficial bacteria. The negative pressure driving mechanism is used for enabling the beneficial bacteria in the feces sample to automatically enter the beneficial bacterium collection bottle (240) after sequentially passing through the filtration and impurity removal device (100), the beneficial bacterium enrichment assembly (220) and the beneficial bacterium dissociation assembly (234). Therefore, directly and selectively screening target beneficial bacteria from feces samples is achieved, and the requirements of accurate transplantation of intestinal flora and accurate treatment of specifically related intestinal diseases in the future can be met.
Resumen de: US20260309706A1
A method for pathogen detection is also disclosed which includes (i) operating a micropump forcing a first fluid hosting a pathogen-selective antibody from a source to a destination, defining a target, via a microfluidic channel, (ii) operating the micropump to thereby force a second fluid potentially hosting the selective pathogen from the source to the destination, obtaining a signal from the destination indicating a mass change; (iii) comparing the mass change to a predetermined threshold to indicate conditional presence of the pathogen and concentration of the pathogen, (iv) operating the micropump forcing a third fluid hosting a pathogen-selective photoluminescent label from the source to the destination, (v) activating a light excitation subsystem, (vi) capturing images from the target; and (vii) analyzing the images to determine presence of the label thus double-confirming a) presence of the pathogen, and b) concentration of the pathogen.
Resumen de: US20260308603A1
Provided are a recombinant expression vector for secretion of CAT protein and an E. coli strain transformed with the vector. Provided are a recombinant expression vector including a flgM gene, a CAT gene, and a flhDC gene, an E. coli strain transformed with the vector, and a pharmaceutical composition for treating cancer, including the E. coli strain as an active ingredient.
Resumen de: US20260306602A1
Provided herein are vaccine compositions comprising Salmonella antigens conjugated to a capsid, wherein said capsid comprises wild type or native sequence, or said capsid may comprise at least one mutation, such as a non-natural mutation; such compositions being useful in the treatment and prevention of a Salmonella infection (salmonellosis), gastroenteritis, typhoid fever, and/or paratyphoid fever; and may be effective against multiple strains of Salmonella.
Resumen de: US20260306554A1
0000 The present disclosure relates to a recombinant expression vector for secretion of an IFN-β protein and an attenuated Salmonella strain transformed therewith, and provides: a recombinant expression vector comprising an flgM gene, an IFN-β gene, and an flhDC gene; an attenuated Salmonella strain transformed therewith; and a pharmaceutical composition for cancer treatment, comprising the attenuated Salmonella strain as an active ingredient.
Resumen de: US20260301973A1
Certain pathogens are known to cause infection in humans or other living hosts. However, harmful pathogens may have thousands of distinct strains or serovars, only a fraction of which may cause a severe or life-threatening infection. Timely identification of strains which are most likely to cause serious infections is problematic. A system and a method are disclosed which provide a diagnostic protocol for identifying virulence groups in one or more pathogens of interest based on genomic features and/or identifying pathogenic markers of higher virulence in hazardous pathogens such as Salmonella enterica which may be used in combination with pathogen surveillance data to optimize the identification of pathogens of public risk and health concern so that the most effective interventions may be selected and applied in a timely manner.
Resumen de: US20260298925A1
Provided are non-naturally occurring systems, methods, and compositions for the detection of microbes. The disclosure relates to the detection of an antigen specific to a microbe, such as a foodborne, an environment-borne, and a bloodborne bacteria, using capture antibody and moiety, detector antibody and moiety, and a light-emitting particle.
Resumen de: EP4814110A1
0001 Provided are a preparation method and application of cryo-shocked monocytes or macrophages loaded with attenuated Salmonella. The method comprises loading engineered attenuated Salmonella into monocytes or macrophages, followed by cryo-shock treatment of monocytes or macrophages loaded with the strain using liquid nitrogen. The method for preparing the cryo-shocked immune cells loaded with the strain is simple and easy to operate, and solves the source problem of the monocytes or macrophages loaded with engineered attenuated Salmonella is solved, thus having good application prospects. This strategy improves the biosafety of bacteria-based anti-tumor therapy by avoiding bacterial exposure and heterologous stimulation; and high intratumoral strain titer promotes an anti-tumor immune response, thereby achieving stronger anti-tumor efficacy.
Resumen de: WO2025037284A2
A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.
Resumen de: CN122811060A
本发明公开了一种重组肠炎沙门菌及其构建方法和应用。本发明通过在肠炎沙门菌同时敲除msbB基因和purL基因，获得减毒的重组肠炎沙门菌，并应用于减毒活疫苗的制备。本发明公开的双基因同时缺失的肠炎沙门菌减毒株毒力较野生型肠炎沙门菌显著下降，在宿主体内定殖时间明显缩短，接种后鸡只无不良反应，对强毒力肠炎沙门菌提供良好的保护作用，可有效清除强毒力菌株感染，对雏鸡提供坚实的免疫保护效果。
Resumen de: WO2026194530A1
The present invention belongs to the field of biomedicine. Provided are a composition for treating tumors using attenuated Salmonella and an immune checkpoint inhibitor, and a method for treating tumors. In the present invention, an anti-tumor immune response is activated by means of the combined use of attenuated Salmonella and an immune checkpoint inhibitor, which synergistically improves the inhibitory effect on tumor cells. The present invention exhibits excellent therapeutic effects against malignant tumors for which effective control means are currently lacking, and has broad application prospects.
Resumen de: US20260284172A1
Disclosed are compositions comprising a fusion polypeptide comprising i) a fusion of a needle tip protein or an antigenic fragment thereof and/or a translocator protein or an antigenic fragment thereof from a Type III secretion system (T3SS) of a Gram negative bacteria and ii) the A1 subunit of the labile toxin (LTA1) from enterotoxigenic Escherichia coli or cholera toxin. and methods of their use.
Resumen de: EP4810124A2
A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.
Resumen de: GB2645265A
Provided is a method for testing the in-vitro bactericidal function of a typhoid vaccine immune serum, comprising: testing the in-vitro bactericidal function of a typhoid vaccine immune serum against Salmonella typhi bacteria by means of an opsonophagocytic killing assay, wherein when the phagocytic killing step of the opsonophagocytic killing assay is completed, the Salmonella typhi bacteria having undergone the phagocytic killing step are cultured at the pH of 7.5-9.5. The opsonophagocytic killing assay is applied to Gram-negative Salmonella Typhi bacteria for the first time, and the in-vitro bactericidal levels of typhoid vaccine immune serums are effectively and accurately evaluated.
Resumen de: WO2024122796A1
The present invention relates to a pharmaceutical composition containing aspartic acid as an active ingredient for the prevention or treatment of sepsis and sepsis-related diseases. Containing aspartic acid as an active ingredient, the composition according to an aspect can achieve the effect of inducing the secretion of inflammatory cytokines during immune tolerance or suppression. Moreover, this effect can increase the survival rate of sepsis animal models, compared to antibiotic-administered groups, whereby the composition can be advantageously applied to the prevention and/or treatment of sepsis or systemic inflammatory response syndrome associated with immune tolerance or suppression.
Resumen de: US20260272995A1
Salmonella typhimurium comprising a first heterologous nucleic acid encoding a first polypeptide that causes bacterial lysis, a second heterologous nucleic acid encoding a second polypeptide that causes vacuolar lysis, and a third heterologous nucleic acid encoding a virus.
Nº publicación: US20260274929A1 17/09/2026
Solicitante:
UNIV MASSACHUSETTS [US]
University of Massachusetts
Resumen de: US20260274929A1
The invention provides anti-ETEC adhesin protein antibodies and methods of using the same.
BOPI
Sede Electrónica
